Montserrat Justo-Garrido

Ms. Montserrat Justo-Garrido

Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Abraham Pedroza-TorresAbraham Pedroza-Torres
Abraham Pedroza-Torres
SRSandra Lorena Romero-Cordoba
Sandra Lorena Romero-Cordoba
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
ISIvan Salido-Guadarrama
Ivan Salido-Guadarrama
RRRubén Rodríguez-Bautista
Rubén Rodríguez-Bautista
LHLuis A. Herrera
Luis A. Herrera
Dysregulated metabolism is a common feature of cancer cells and is considered a hallmark of cancer. Altered tumor-metabolism confers an adaptive advantage to cancer cells to fulfill the high energetic requirements for the maintenance of high proliferation rates, similarly, reprogramming metabolism confers the ability to grow at low oxygen concentrations and to use alternative carbon sources. These phenomena result from the dysregulated expression of diverse genes, including those encoding microRNAs (miRNAs) which are involved in several metabolic and tumorigenic pathways through its post-transcriptional-regulatory activity. Further, the identification of key actionable altered miRNA has allowed to propose novel targeted therapies to modulated tumor-metabolism. In this review, we discussed the different roles of miRNAs in cancer cell metabolism and novel miRNA-based strategies designed to target the metabolic machinery in human cancer.

Verified
Journal Article
Open access
PDF file
MEMarco Alonso Andonegui Elguera
Marco Alonso Andonegui Elguera
RCRodrigo E. Cáceres-Gutiérrez
Rodrigo E. Cáceres-Gutiérrez
Alejandro Lopez-SaavedraAlejandro Lopez-Saavedra
Alejandro Lopez-Saavedra
FSFernanda Cisneros Soberanis
Fernanda Cisneros Soberanis
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
LHLuis A. Herrera
Luis A. Herrera
During mitosis, many cellular structures are organized to segregate the replicated genome to the daughter cells. Chromatin is condensed to shape a mitotic chromosome. A multiprotein complex known as kinetochore is organized on a specific region of each chromosome, the centromere, which is defined by the presence of a histone H3 variant called CENP-A. The cytoskeleton is re-arranged to give rise to the mitotic spindle that binds to kinetochores and leads to the movement of chromosomes. How chromatin regulates different activities during mitosis is not well known. The role of histone post-translational modifications (HPTMs) in mitosis has been recently revealed. Specific HPTMs participate in local compaction during chromosome condensation. On the other hand, HPTMs are involved in CENP-A incorporation in the centromere region, an essential activity to maintain centromere identity. HPTMs also participate in the formation of regulatory protein complexes, such as the chromosomal passenger complex (CPC) and the spindle assembly checkpoint (SAC). Finally, we discuss how HPTMs can be modified by environmental factors and the possible consequences on chromosome segregation and genome stability.

8 July 2016 in Cell Cycle
Verified
Journal Article
Open access
Alejandro Lopez-SaavedraAlejandro Lopez-Saavedra
Alejandro Lopez-Saavedra
MRMiguel Ramírez-Otero
Miguel Ramírez-Otero
Jose Diaz-ChavezJose Diaz-Chavez
Jose Diaz-Chavez
RCRodrigo Cáceres-Gutiérrez
Rodrigo Cáceres-Gutiérrez
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
LHLuis A. Herrera
Luis A. Herrera
Background: Prolonged mitotic arrest in response to anti-cancer chemotherapeutics, such as DNA-damaging agents, induces apoptosis, mitotic catastrophe, and senescence. Disruptions in mitotic checkpoints contribute resistance to DNA-damaging agents in cancer. MAD2 has been associated with checkpoint failure and chemotherapy response. In this study, a novel splice variant of MAD2, designated MAD2γ, was identified, and its association with the DNA damage response was investigated. Methods: Endogenous expression of MAD2γ and full-length MAD2 (MAD2α) was measured using RT-PCR in cancer cell lines, normal foreskin fibroblasts, and tumor samples collected from patients with testicular germ cell tumors (TGCTs). A plasmid expressing MAD2γ was transfected into HCT116 cells, and its intracellular localization and checkpoint function were evaluated according to immunofluorescence and mitotic index. Results: MAD2γ was expressed in several cancer cell lines and non-cancerous fibroblasts. Ectopically expressed MAD2γ localized to the nucleus and reduced the mitotic index, suggesting checkpoint impairment. In patients with TGCTs, the overexpression of endogenous MAD2γ, but not MAD2α, was associated with resistance to cisplatin-based chemotherapy. Likewise, cisplatin induced the overexpression of endogenous MAD2γ, but not MAD2α, in HCT116 cells. Conclusions: Overexpression of MAD2γ may play a role in checkpoint disruption and is associated with resistance to cisplatin-based chemotherapy in TGCTs.

18 June 2026 in Cancer Research
Verified
Journal Article
Closed access
MFMona Foth
Mona Foth
WKWontak Kim
Wontak Kim
KOKayla OToole
Kayla OToole
BMBrandon Murphy
Brandon Murphy
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
MMMartin McMahon
Martin McMahon
Most patients with advanced BRAF- or NRAS-driven melanoma receive first-line immunotherapy. However, if immunotherapy fails, BRAF-mutated patients receive effective second-line therapies, whereas NRAS-mutated patients lack pathway-targeted options. Recently, RAS(ON) multiselective inhibitors like RMC-7977 and the investigational agent daraxonrasib were described that inhibit RAS[GTP] signaling in partnership with cyclophilin A (CYPA). In this study, we found that both compounds demonstrated potent antiproliferative activity against NRAS-mutated melanoma cell lines and robust antitumor activity against preclinical melanoma models. However, in preclinical models, resistance to RMC-7977 monotherapy arose through mutations in Ppia (encoding CYPA) or Map2k1 (encoding MEK1). Moreover, 2 clinical case studies in patients with NRAS-mutated melanoma treated with daraxonrasib demonstrated clear antitumor activity in 1 patient but progressive disease in another with co-occurring NRAS and MAP2K1 mutations at baseline. These findings support the potential for daraxonrasib in the treatment of patients with NRAS-mutated melanoma and reveal candidate mechanisms of monotherapy resistance, underscoring the need for combination therapies to improve outcomes. Significance: Inhibition of RAS signaling with RMC-7977 or daraxonrasib displays potent activity in models of NRAS-driven melanoma, with drug resistance mediated by mutational silencing of CYPA expression or activation of MEK1.

Verified
Journal Article
Open access
PDF file
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
Alejandro Lopez-SaavedraAlejandro Lopez-Saavedra
Alejandro Lopez-Saavedra
NANicolás Alcaraz
Nicolás Alcaraz
Carlo C Cortes-GonzalezCarlo C Cortes-Gonzalez
Carlo C Cortes-Gonzalez
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña
LHLuis A. Herrera
Luis A. Herrera
Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
OPOmar Peña-Curiel
Omar Peña-Curiel
DPDiddiera Prada
Diddiera Prada
MOMiguel Otero
Miguel Otero
JDJosé Díaz-Chávez
José Díaz-Chávez
CVCynthia Villarreal-Garza
Cynthia Villarreal-Garza
LMLuis Alonso Herrera Montalvo
Luis Alonso Herrera Montalvo
E23173 Background: Breast cancer is one of the top causes of cancer death worldwide. In Mexico, locally advanced breast cancer (LABC) comprises the majority of the breast cancer stages at diagnosis. Recent studies have suggested that 5-hydroxymethylcytosine (5hmC), could be a prognostic marker in breast cancer. However, the role of 5hmC on clinical and histopathologic characteristics in LABC has not been explored. Methods: From a cohort of locally advanced and advanced breast cancer patients treated at the National Cancer Institute in Mexico City with a 3-year follow-up, we measured 5hmC levels by immunodetection from fresh frozen tissue samples taken from the initial biopsy (N = 193). We determined the association between 5hmC levels and the most relevant clinical and histopathological characteristics. Results: From the full cohort analyzed; 42% were luminal A (n = 82), 33% were luminal B (N = 63), 9% were HER2-positive (N = 18), and 15% were triple-negative tumors. We found higher levels of global 5hmC in HER2 positive tumors vs. all other subtypes (p = 0.028, Kruskal-Wallis test). In luminal B tumors, 5hmC levels were associated with Ki67 (β = -0.04, 95%CI: -0.08, -0.01, p = 0.01 from multivariable model) but not in luminal A. Furthermore, we found that low 5hmC levels were associated with higher histological grade in HER2-positive tumors (p = 0.03, Kruskal-Wallis test). In subgroup analysis of LABC patients, we found higher 5hmC levels in non-ductal vs. ductal invasive tumors (β = 1.38, 95%CI: 0.049, 2.911, p = 0.043 from multivariable model). Also, lower 5hmC levels were associated with Ki67 (β = -2.53, 95%CI: -4.32, -0.74; p = 0.009 from multivariable model) and with histological type (p = 0.028, Kruskal-Wallis test) in LABC luminal B tumors. A borderline association with OS (p = 0.07, log-rank test) and RFS (p = 0.071, log-rank test) was observed in luminal A tumors in the LABC group. Conclusions: Our findings suggest that 5hmC levels are differentially associated with distinct clinical and histopathological characteristics in breast cancer, especially those linked to aggressiveness, including Ki67, histological type, and grade.